At AGBT Roche provided technical and commercial details for its Axelios 1 sequencing platform, touting a $150 list cost to sequence a human genome at 30× coverage in duplex mode. The company disclosed instrument pricing and throughput expectations and positioned Axelios against competing platforms from Illumina, Ultima and others. Roche said the platform will be available for preorder with formal launch planned later in the year; the company highlighted use cases spanning cancer genomics and multi‑omics. Industry watchers cautioned that real‑world cost efficiency, run yields and data quality will determine market uptake as labs evaluate alternatives.